Wall Street Zen Downgrades Align Technology (NASDAQ:ALGN) to Buy

Align Technology (NASDAQ:ALGN) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

ALGN has been the subject of several other reports. Citigroup initiated coverage on Align Technology in a research report on Wednesday, April 15th. They issued a “buy” rating and a $240.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Align Technology in a report on Thursday. Evercore lifted their price target on shares of Align Technology from $200.00 to $220.00 in a research note on Thursday, April 30th. Weiss Ratings upgraded shares of Align Technology from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 17th. Finally, Morgan Stanley increased their price objective on shares of Align Technology from $169.00 to $188.00 and gave the stock an “equal weight” rating in a research report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Align Technology currently has an average rating of “Moderate Buy” and a consensus price target of $206.36.

Align Technology Stock Performance

ALGN stock opened at $169.16 on Friday. Align Technology has a 1-year low of $122.00 and a 1-year high of $200.43. The firm has a market cap of $12.12 billion, a PE ratio of 29.42, a P/E/G ratio of 1.78 and a beta of 1.65. The business’s 50-day moving average price is $174.55 and its two-hundred day moving average price is $175.23.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.02. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. Align Technology had a return on equity of 15.86% and a net margin of 9.99%.The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.49 earnings per share. On average, analysts forecast that Align Technology will post 9.48 earnings per share for the current year.

Align Technology declared that its board has authorized a stock repurchase program on Wednesday, April 29th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the medical equipment provider to repurchase up to 1.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Align Technology

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Handelsbanken Fonder AB grew its stake in shares of Align Technology by 5.2% during the 2nd quarter. Handelsbanken Fonder AB now owns 26,474 shares of the medical equipment provider’s stock worth $4,465,000 after acquiring an additional 1,310 shares in the last quarter. First Bank & Trust lifted its position in shares of Align Technology by 5.0% in the second quarter. First Bank & Trust now owns 1,599 shares of the medical equipment provider’s stock worth $270,000 after purchasing an additional 76 shares in the last quarter. Contravisory Investment Management Inc. bought a new stake in shares of Align Technology in the second quarter worth $1,106,000. Beacon Investment Advisory Services Inc. boosted its holdings in Align Technology by 14.7% during the second quarter. Beacon Investment Advisory Services Inc. now owns 3,081 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 394 shares during the last quarter. Finally, Czech National Bank boosted its holdings in Align Technology by 4.3% during the second quarter. Czech National Bank now owns 18,958 shares of the medical equipment provider’s stock worth $3,197,000 after purchasing an additional 785 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

Key Stories Impacting Align Technology

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Q2 results exceeded expectations. Align reported adjusted earnings of $2.64 per share and revenue of approximately $1.06 billion, topping consensus estimates. Revenue increased 4.3% year over year, while record Clear Aligner shipments and improved non-GAAP margins supported profitability. Align Technology Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Digital orthodontics remains a growth focus. Management highlighted expanding digital workflows, connected orthodontic tools and long-term opportunities for Invisalign, iTero scanners and exocad software. The company’s 2026 outlook was reaffirmed, while an orthodontic summit showcased its product and technology strategy. ALGN Q2 Earnings Call Highlights Digital Growth Push
• Positive Sentiment: Board changes could improve shareholder value. Following discussions with Elliott Investment Management, Align plans to add three independent directors and conduct an operational review. The initiatives may increase accountability, improve execution and identify opportunities to enhance returns. Align Technology to Overhaul Board Following Engagement with Elliott
• Neutral Sentiment: Valuation is viewed as more attractive after the pullback. Some analysts see ALGN as reasonably valued, but believe the stock needs faster growth to generate sustained upside. Align Technology: Attractively Valued, But Growth Still Needs To Pick Up
• Negative Sentiment: Near-term guidance and execution remain concerns. Third-quarter revenue guidance of roughly $1.0 billion was described as slightly below or around expectations, limiting the benefit of the earnings beat.
• Negative Sentiment: Systems weakness is capping upside. Analysts noted softer scanner and systems performance, along with pricing pressure, despite strong Clear Aligner volumes. Needham maintained a Hold rating. Align Technology Hold Rating Maintained
• Negative Sentiment: Growth is still relatively modest. Investors may remain cautious because revenue growth has not yet accelerated enough to justify a more bullish outlook, even with improving margins and record aligner shipments.

Align Technology Company Profile

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.